<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Moderna Inc. MRNA, -0.85% were down 0.5% in premarket trading on Wednesday after the company said it began dosing participants in a Phase 1 clinical trial evaluating the company’s experimental Epstein-Barr virus vaccine. The virus causes mononucleosis, also called mono, and is associated with a higher risk of multiple sclerosis and some lymphoproliferative disorders.
...read full article on Market Watch
